Although PD-1 or PD-L1 drugs are widely used in lung cancer and melanoma, research on their impacts on triple-negative breast cancer, a refractory breast tumor, is still very limited, as is research on their safety. Here, PDCD1 is linked to triple-negative breast carcinoma.